EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation

References

• BottoLDMooreCAKhouryMJEricksonJDNeural tube defectsN Engl J Med19993411509151910559453
   PubMed Web of Science ®Google Scholar
• [No authors listed]Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research GroupLancet19913381311371677062
   PubMed Web of Science ®Google Scholar
• DalyLEKirkePNMolloyAWeirDGScottJMFolate levels and neural tube defects. Implications for preventionJAMA1995274169817027474275
   PubMed Web of Science ®Google Scholar
• BusbyAAbramskyLDolkHPreventing neural tube defects in Europe: a missed opportunityReprod Toxicol20052039340215927445
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task ForceFolic acid for the prevention of neural tube defects: US Preventive Services Task Force recommendation statementAnn Intern Med200915062663119414842
   PubMed Web of Science ®Google Scholar
• European Surveillance of Congenital Anomalies (EUROCAT)Folic acid special reports: survey of folic acid policy and practice in European countries, Dec 2007 Available from: http://www.eurocat-network.eu/preventionandriskfactors/folicacid/folicacidspecialreportsAccessed January 24, 2013
   Google Scholar
• SmithellsRWSheppardSSchorahCJPossible prevention of neural tube defects by periconceptional vitamin supplementationLancet198013393406101792
   PubMed Web of Science ®Google Scholar
• LaurenceKMJamesNMillerMHTennantGBCampbellHDoubleblind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defectsBr Med J (Clin Res Ed)198128215091511
   PubMed Web of Science ®Google Scholar
• MulinareJCorderoJFEricksonJDBerryRJPericonceptional use of multivitamins and the occurrence of neural tube defectsJAMA1988260314131453184392
   PubMed Web of Science ®Google Scholar
• BowerCStanleyFJDietary folate as a risk factor for neural-tube defects: evidence from a case-control study in western australiaMed J Aust19891506136192725375
   PubMed Web of Science ®Google Scholar
• MitchellACase control study of neural tube defects and periconceptional vitamin usePaediatr Perinat Epidemiol198932162734238
   PubMedGoogle Scholar
• VergelRGSanchezLRHerederoBLRodriguezPLMartinezAJPrimary prevention of neural tube defects with folic acid supplementation: Cuban experiencePrenat Diagn1990101491522343028
   PubMed Web of Science ®Google Scholar
• CzeizelAEDudasIPrevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementationN Engl J Med1992327183218351307234
   PubMed Web of Science ®Google Scholar
• WerlerMMShapiroSMitchellAAPericonceptional folic acid exposure and risk of occurrent neural tube defectsJAMA1993269125712618437302
   PubMed Web of Science ®Google Scholar
• ShawGMSchafferDVelieEMMorlandKHarrisJAPericonceptional vitamin use, dietary folate, and the occurrence of neural tube defectsEpidemiology199562192267619926
   PubMed Web of Science ®Google Scholar
• BerryRJLiZEricksonJDPrevention of neural-tube defects with folic acid in china. China-US. Collaborative project for neural tube defect preventionN Engl J Med19993411485149010559448
   PubMed Web of Science ®Google Scholar
• De-RegilLMFernandez-GaxiolaACDowswellTPena-RosasJPEffects and safety of periconceptional folate supplementation for preventing birth defectsCochrane Database Syst Rev201010CD00795020927767
   PubMed Web of Science ®Google Scholar
• MathewsTJHoneinMAEricksonJDSpina bifida and anencephaly prevalence – United States, 1991–2001MMWR Recomm Rep20025191112353510
   PubMedGoogle Scholar
• RayJGSinghGBurrowsRFEvidence for suboptimal use of pericon-ceptional folic acid supplements globallyBJOG200411139940815104602
   PubMed Web of Science ®Google Scholar
• TinkerSCCogswellMEDevineOBerryRJFolic acid intake among US women aged 15–44 years, National Health and Nutrition Examination Survey, 2003–2006Am J Prev Med20103853454220347553
   PubMed Web of Science ®Google Scholar
• Spina bifida and anencephaly before and after folic acid mandate – United States, 1995–1996 and 1999–2000MMWR Morb Mortal Wkly Rep20045336236515129193
   PubMedGoogle Scholar
• US Food and Drug AdministrationSummary minutes advisory committee for reproductive health drugs meeting, December 15, 2003 Available from: http://www.fda.gov/ohrms/dockets/ac/03/minutes/4002M1_Final.pdfAccessed January 24, 2013
   Google Scholar
• LassiZSBhuttaZAClinical utility of folate-containing oral contraceptivesInt J Womens Health2012418519022570577
   PubMedGoogle Scholar
• LamersYPrinz-LangenohlRBramswigSPietrzikKRed blood cell folate concentrations increase more after supplementation with [6s]-5-methyltetrahydrofolate than with folic acid in women of childbearing ageAm J Clin Nutr20068415616116825690
   PubMed Web of Science ®Google Scholar
• LamersYPrinz-LangenohlRMoserRPietrzikKSupplementation with [6s]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy womenAm J Clin Nutr20047947347814985224
   PubMed Web of Science ®Google Scholar
• VennBJGreenTJMoserRMannJIComparison of the effect of low-dose supplementation with l-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled studyAm J Clin Nutr20037765866212600857
   PubMed Web of Science ®Google Scholar
• VennBJGreenTJMoserRMcKenzieJESkeaffCMMannJIncreases in blood folate indices are similar in women of childbearing age supplemented with [6s]-5-methyltetrahydrofolate and folic acidJ Nutr20021323353335512421850
   PubMed Web of Science ®Google Scholar
• PietrzikKBaileyLShaneBFolic acid and l-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamicsClin Pharmacokinet20104953554820608755
   PubMed Web of Science ®Google Scholar
• Yaz [prescribing information]Berlin, GermanyBayer HealthCare Pharmaceuticals Inc2012
   Google Scholar
• PernetPLasnierEVaubourdolleMEvaluation of the AxSym homocysteine assay and comparison with the IMX homocysteine assayClin Chem2000461440144110973885
   PubMed Web of Science ®Google Scholar
• SmithDEKokRMTeerlinkTJakobsCSmuldersYMQuantitative determination of erythrocyte folate vitamer distribution by liquid chromatography-tandem mass spectrometryClin Chem Lab Med20064445045916599840
   PubMed Web of Science ®Google Scholar
• BakkerDJde Jong-van den BergLTFokkemaMRControlled study on folate status following folic acid supplementation and discontinuation in women of child-bearing ageAnn Clin Biochem20094623123419342442
   PubMed Web of Science ®Google Scholar
• HaoLYangQHLiZFolate status and homocysteine response to folic acid doses and withdrawal among young chinese women in a large-scale randomized double-blind trialAm J Clin Nutr20088844845718689382
   PubMed Web of Science ®Google Scholar
• HesekerHSchmittGEffect of long-term supplementation of folate on folate status in plasma and erythrocytesJ Nutr Sci Vitaminol (Tokyo)1987331631683668697
   PubMed Web of Science ®Google Scholar
• BlodeHKlippingCRichardFTrummerDRohdeBDiefenbachKBioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to Yaz® and to levomefolate calcium aloneContraception20128517718422067789
   PubMed Web of Science ®Google Scholar
• PentievaKMcNultyHReichertRThe short-term bioavailabilities of [6s]-5-methyltetrahydrofolate and folic acid are equivalent in menJ Nutr200413458058514988450
   PubMed Web of Science ®Google Scholar
• VollsetSERefsumHIrgensLMPlasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: The Hordaland Homocysteine StudyAm J Clin Nutr20007196296810731504
   PubMed Web of Science ®Google Scholar
• BartSSMarrJDiefenbachKTrummerDSampson-LandersCFolate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, us-based, multicenter studyContraception201285425022067790
   PubMed Web of Science ®Google Scholar
• PietrzikKLamersYBramswigSPrinz-LangenohlRCalculation of red blood cell folate steady state conditions and elimination kinetics after daily supplementation with various folate forms and doses in women of childbearing ageAm J Clin Nutr2007861414141917991654
   PubMed Web of Science ®Google Scholar
• HursthouseNAGrayARMillerJCRoseMCHoughtonLAFolate status of reproductive age women and neural tube defect risk: the effect of long-term folic acid supplementation at doses of 140 μg and 400 μg per dayNutrients20113496222254076
   PubMed Web of Science ®Google Scholar
• CroninMSchellschmidtIDingerJRate of pregnancy after using drospirenone and other progestin-containing oral contraceptivesObstet Gynecol200911461662219701043
   PubMed Web of Science ®Google Scholar
• BachmannGSulakPJSampson-LandersCBendaNMarrJEfficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenoneContraception20047019119815325887
   PubMed Web of Science ®Google Scholar
• CroninMKornerPThe safety profile of Yasmin is similar to other combined oral contraceptivesClin Appl Thromb Hemost20081424524618372279
   PubMed Web of Science ®Google Scholar
• EndrikatJMullerUDusterbergBA twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and toleranceContraception1997551311379115000
   PubMed Web of Science ®Google Scholar